Edwards Lifesciences (EW) Profit After Tax (2009 - 2026)

Edwards Lifesciences' Profit After Tax history runs 18 years deep, the most recent figure standing at $380.7 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 4.7% year-over-year to $380.7 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 74.33% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 74.7% from the prior year.
• Profit After Tax advanced to $380.7 million in Q1 2026 per EW's latest filing, from $60.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at $3.1 billion in Q3 2024 and bottomed at $60.1 million in Q4 2025.
• The 5-year median for Profit After Tax is $345.0 million (2024), against an average of $485.0 million.
• Across the five-year window, Profit After Tax surged 3406.19% in 2022 and sank 90.52% in 2025, its largest moves.
• Year by year, Profit After Tax stood at $200.5 million in 2022, then surged by 66.13% to $333.1 million in 2023, then grew by 3.57% to $345.0 million in 2024, then plunged by 82.58% to $60.1 million in 2025, then surged by 533.44% to $380.7 million in 2026.
• Per Business Quant, the three latest EW Profit After Tax figures stand at $380.7 million (Q1 2026), $60.1 million (Q4 2025), and $291.1 million (Q3 2025).